GALDERMA
28.9.2021 08:32:08 CEST | Business Wire | Press release
Galderma’s presence at the 2021 European Academy of Dermatology and Venereology (EADV) virtual congress on September 29 – October 2 will reveal new data and showcase the company’s sophisticated portfolio and services across the spectrum of dermatology. The company’s redesigned virtual booth will have dedicated areas presenting Galderma’s innovations in Consumer Care and Prescription Medicine.
Unveiling new data in Prescription Medicine
The congress will see the unveiling of exciting new data from Galderma relating to rosacea, acne, actinic keratosis, atopic dermatitis and prurigo nodularis. Attendees will have the opportunity to ask questions to the faculties during live Q&A sessions.
On Thursday, September 30, Professor Alison Layton^ will chair the symposium Personalizing Acne: Consensus of Experts to Optimize Acne Management . Together with her co-speakers, Professor Layton will provide practical solutions for longitudinal management of acne.
On the same day, Professor Gil Yosipovitch^ will present the symposium Prurigo Nodularis: From Patient to Pathway, which will discuss the multi-dimensional impact of the disease and reveal new clinical data for the investigational drug, nemolizumab*.
The symposium Moderate to Severe Atopic Dermatitis – A Disease in the Skin and Beyond will take place on Friday, October 1. Chaired by Professor Diamant Thaçi, the session will cover the role of neuro-immune cytokine IL-31 in atopic dermatitis and present emerging clinical data on the effect of nemolizumab* in blocking IL-31 signaling in the disease.
In the symposium New insights on Papulopustular Rosacea and Systemic Therapy on October 1, the speakers will discuss the importance of long-term management strategies in rosacea. Dr. James Q. Del Rosso^ will present original data on the impact of 52 weeks’ use of doxycycline 40mg MR on relapse rate in moderate to severe papulopustular rosacea patients.
On Saturday, October 2, Professor Rolf-Markus Szeimies^ and Professor Serge Mordon^ will host the industry hub Artificial Daylight Photodynamic Therapy: Advancing Actinic Keratosis Treatment . They will present the newly approved modality and main approved artificial daylight devices, as well as a demonstration video.
Galderma will also showcase its latest acne treatment, AKLIEF® (trifarotene) Cream, 0.005%, specifically designed for both facial and truncal acne.
Showcasing advanced solutions in Consumer Care
Visitors will be able to explore highlights from the CETAPHIL® portfolio of 61 products and the largest update in the brand’s 70-year history. As part of the update, CETAPHIL’s iconic, best-selling cleansers and moisturizers—Gentle Skin Cleanser, Daily Facial Cleanser, Moisturizing Cream, Moisturizing Lotion, and Advanced Relief Lotion—have been reformulated. With their dermatologist-backed blend of hydrating and skin-nourishing ingredients, including niacinamide, panthenol and hydrating glycerin, the range of products helps improve the overall resilience of sensitive skin.
CETAPHIL’s latest research will be unveiled through two dedicated symposia. On Thursday, September 30, Dr. Krzysztof Piotrowski^ will chair the symposium Pediatric Atopic Dermatitis: Current Developments . Professor Adelaide Hebert^ will focus on the latest updates in the field of pediatric atopic dermatitis while Dr. Mark Koh^ will then present his findings and answer the question, “Is it possible to prevent atopic dermatitis from birth?”.
On Friday, October 1, Professor Giovanni Pellacani^ will chair the symposium Advancing Sensitive Skin: Diagnosis, Morphological Traits and Epidemiology . Key speakers Professor Laurent Misery^ and Dr. Emilie Brenaut^ will present their latest research findings and focus on what sensitive skin is, how it can be distinguished from non-sensitive skin and methods for profiling.
Experts from BENZAC® and LOCERYL® will present new findings relating to maskne and onychomycosis through two industry hubs: on Thursday, September 30, Dr. Markus Reinholz^ will chair The Many Faces of Maskne – a New Skin Burden / an Upcoming Disease , featuring speaker Dr. Anne-Charlotte Kuna^. On Friday, October 1, Dr. Dieter Reinel^ will host Onychomycosis Update – Novel Findings: Prevalence, Epidemiology and Topical Therapy .
* Nemolizumab is an investigational drug not approved for any indication in any jurisdiction.
^All speakers are paid consultants of Galderma.
“Galderma is a proud partner of the EADV Congress and we are thrilled to be showcasing our latest innovations and data across our dermatology portfolio. As a company, we are fully committed to advancing dermatology for every skin story.”
BALDO SFORZOLINI, Ph.D. GLOBAL HEAD OF R&D, GALDERMA
|
About Galderma
Galderma is the world’s largest independent dermatology company, present in approximately 100 countries. Since our inception in 1981, we have been driven by a complete dedication to dermatology. We deliver an innovative, science-based portfolio of sophisticated brands and services across Aesthetics, Consumer Care and Prescription Medicine. Focused on the needs of consumers and patients, we work in partnership with healthcare professionals to ensure superior outcomes. Because we understand that the skin we’re in shapes our life stories, we are advancing dermatology for every skin story. For more information:
About prurigo nodularis
Prurigo nodularis (PN) is a rare, potentially debilitating, chronic skin condition with thick skin nodules covering large body areas and associated intense unrelenting itch.10
While PN can occur at any age, it is most likely to affect people between the ages of 40 and 69, frequently leading to severe impairment in quality of life.11
The global prevalence of PN is unknown as there are no studies describing the epidemiology of the condition. In the U.S., the latest estimate is that PN affects 52.9 people in every 100,000. In the European context, rates of between 0.65 and 11.1 per 10,000 population have been reported. In addition to natural variation, this relatively wide range of estimates is partly due to differences in case definition and the representativeness of the study populations.12
About nemolizumab
Nemolizumab is a first-in-class humanized monoclonal antibody directed against the IL-31 receptor alpha that blocks signaling from IL-31.6
IL-31 plays a key role in multiple disease mechanisms in both atopic dermatitis and prurigo nodularis, a rare, potentially debilitating, chronic skin condition with thick skin nodules covering large body areas and associated severe pruritus (itching). With its unique role in directly stimulating sensory neurons related to itch and contributing to inflammation and barrier dysfunction, IL-31 is the bridge between the immune and nervous systems while directly acting on structural cells in the skin. Nemolizumab, initially developed by Chugai Pharmaceutical Co., Ltd., was subsequently licensed to Galderma in 2016 – worldwide except Japan and Taiwan. Nemolizumab is an investigational agent under clinical development for the treatment of atopic dermatitis and prurigo nodularis and its safety and efficacy have not been fully evaluated by any regulatory authority. Nemolizumab was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) in December 2019 for the treatment of pruritus associated with prurigo nodularis.
About AKLIEF
In the European Union, AKLIEF®
(trifarotene 50 mcg/g cream) is indicated for the cutaneous treatment of acne vulgaris of the face and/or the trunk in patients from 12 years of age and older, when many comedones, papules and pustules are present. It is the only topical retinoid that specifically targets retinoic acid receptor gamma (RAR-γ), the most common RAR in the skin.13, 14
National marketing authorizations across concerned European member states will follow in 2020.
About CETAPHIL
CETAPHIL was developed by a leading pharmacist more than 70 years ago as a gentle, yet powerful formula to clean without stripping and moisturize without clogging. CETAPHIL is the #1 dermatologist-recommended brand in Germany and the #1 doctor-recommended sensitive skincare brand in the U.S. and is now available in Switzerland. New additions to the brand are regularly developed with the help of leading global skincare experts, providing innovative skincare technologies for sensitive skin that help restore, protect, and maintain skin health every day. For more information, visit www.cetaphil.com
.
About BENZAC
BENZAC is an acne brand proposing treatments based on Benzoyl Peroxide active ingredient, as well as acne specific regimen companion products (including cleansers and moisturizers).
About LOCERYL
LOCERYL is the number one nail antifungal brand globally.16
Its treatment is based on amorolfine active ingredient.
-----------------
1. Tan J, et al. Prevalence and severity of facial and truncal acne in a referral cohort. J Drugs Dermatol. 2008;7(6):551–6.
2. Bhate K, Williams HC. Epidemiology of acne vulgaris. Br J Dermatol 2013;168:474–85.
3. Hay RJ, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol 2014;134:1527–34.
4. Del Rosso JQ, et al. A closer look at truncal acne vulgaris: prevalence, severity, and clinical significance. J Drugs Dermatol 2007;6:597–600.
5. Layton AM, et al. Reviewing the global burden of acne: how could we improve care to reduce the burden? Br J Dermatol 2021;184:219–225.
6. Saleem M. et al. Interleukin-31 pathway and its role in atopic dermatitis: a systematic review. J Dermatolog Treat. 2017;28(7):591-599. DOI: 10.1080/09546634.2017.1290205
7. Langan S. et al. Atopic dermatitis. The Lancet. 2020;396(10247):345-360. DOI: https://doi.org/10.1016/S0140-6736(20)31286-1
8. Nutten S. Atopic Dermatitis: Global Epidemiology and Risk Factors. Ann Nutr Metab 2015;66(suppl1):8-16. DOI: https://doi.org/10.1159/000370220
9. Atopic Eczema – Symptoms. NHS. Available from: https://www.nhs.uk/conditions/atopic-eczema/symptoms/ Accessed: March 2021.
10. Galderma. Data on File.
11. Atopic Eczema – Symptoms. NHS. Available from: https://www.nhs.uk/conditions/atopic-eczema/symptoms/ Accessed: March 2021
12. Morgan LI. Christopher. Epidemiology of prurigo nodularis in England. 2021.
13. Aubert J, et al. Br J Dermatol 2018;179:442–56.
14. Fisher GJ, et al. J Biol Chem 1994;269(32):20629–35.
15. Health Canada. Approval of Aklief. Available at: Register of Innovative Drugs - Canada.ca (last access December 2019)
16. Nicholas Hall’s global CHC database, DB6
View source version on businesswire.com: https://www.businesswire.com/news/home/20210927005918/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press release
Barilla continues to advance its commitment to tastier products with less sugar and salt;An investment of 30 million euros in 2025 to quadruple photovoltaic capacity across plants, as part of a €168 million five-year plan focused on energy efficiency, renewable energy and sustainable water management.Barilla continues to expand regenerative agriculture practices across its global value chain, with over 816,000 tons of raw materials sourced through the Barilla Sustainable Farming program.4,000 tons of products donated worldwide and €2 million allocated to social causes in 2025, supporting communities across Barilla’s global footprint through food donations and social initiatives. A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal oppor
PUMA and Salehe Bembury Host Immersive Sound-Inspired Experience ahead of Football’s Biggest Tournament at The Row DTLA5.6.2026 09:59:00 CEST | Press release
Event Celebrated the launch of the PUMA x Salehe Bembury TRVL WEAR Collection and Velum 1 to be worn by PUMA’s 11 Federations this summer Global sports company PUMA and visionary designer Salehe Bembury hosted an immersive experience at The Row DTLA celebrating their collaboration ahead of football's biggest global tournament. The activation transformed the historic venue into a series of interactive environments, offering guests an inside look into the creative world behind the partnership. Set against the backdrop of Los Angeles, the event brought football beyond the pitch and into everyday life through the lens of sound and design. The PUMA x SALEHE BEMBURY collaboration kicks off PUMA’s second chapter of football introductions this summer, following the launch of their 11 national federation kits in March. This more streetwear-oriented launch introduces a bespoke collection of travel wear and goalkeeper kits for PUMA’s 11 national federations in the tournament. This press release f
Azafaros Announces Publication of Phase 2 RAINBOW Study Data for Nizubaglustat in Molecular Genetics and Metabolism Journal5.6.2026 07:00:00 CEST | Press release
Phase 2 RAINBOW study data showed that treatment with nizubaglustat in patients with GM2 gangliosidosis (GM2) and Niemann-Pick type C disease (NPC) reduced disease progression and seizure burdenTopline results from the study announced in 2024 demonstrated that nizubaglustat was safe and well tolerated, with encouraging signs of efficacyThe published data further supports the two ongoing registrational Phase 3 studies with nizubaglustat in GM1/GM2 and NPC Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced the publication of clinical data from its Phase 2 (RAINBOW) study in the peer reviewed journal, Molecular Genetics & Metabolism. The published manuscript reports efficacy, safety, pharmacokinetic and pharmacodynamic data which evaluated nizubaglustat in patients with genetically confirmed GM2 gangliosidosis and NPC. As previously stated in the topline results announcemen
K-Startup Grand Challenge 2026: Korea's Full-Cycle Launchpad for Global Startups5.6.2026 03:00:00 CEST | Press release
KSGC 2026 provides end-to-end support - from market entry to sustainable growth - positioning Korea as the gateway for Asia expansion South Korea’s Ministry of SMEs and Startups (MSS) has opened applications for the K-Startup Grand Challenge (KSGC), the country’s premier government-backed acceleration program for international startups targeting Korea and Asia. Since 2016, KSGC has attracted 21,537 applicants from more than 100 countries, among the world's most recognized inbound programs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604794426/en/ South Korea’s Ministry of SMEs and Startups (MSS) has opened applications for K-Startup Grand Challenge 2026, a government-backed global startup acceleration program providing end-to-end support for international startups (Image: KSGC) A Full-Cycle Acceleration Journey Unlike conventional programs that focus on a single moment of market entry, KSGC 2026 guides startups from ma
Empire State Building Observation Deck Celebrates Soccer with World’s Most Iconic Soccer Jersey Exhibit, Custom ESB Jerseys, Player Visits, Lightings, and More4.6.2026 23:46:00 CEST | Press release
The Empire State Building Observation Deck (ESB) – the #1 Attraction in the United States – today announced further 2026 programming for soccer fans in New York City with the world’s most iconic jersey collection from the Classic Football Shirts (CFS) vault, a limited-edition ESB x CFS jersey, official merch giveaways, and special lightings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604370013/en/ Empire State Building Observation Deck Celebrates Soccer with World’s Most Iconic Soccer Jersey Exhibit, Custom ESB Jerseys, Player Visits, Lightings, and More “As the world descends upon New York City for this anticipated global soccer event, fans can visit the Empire State Building Observation Deck for Manhattan’s best skyline views and a one-of-a-kind soccer exhibit,” said Dan Rogoski, observatory general manager. “International and American soccer fans can extend the celebration off the pitch at the #1 Attraction in the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom